With high stakes to satisfy unmet patient needs, cell therapy is a promising but challenging field of oncology. There is a crucial need to progress candidates from bench to bedside.
Fresh from a licensing agreement with Pfizer, US startup Pyxis Oncology has raised a sizeable $152 million in second-round financing led by venture capital groups Arix Bioscience and RTW In
US biotech Aura Biosciences has closed an oversubscribed financing, raising $80 million to help take its lead virus-like drug conjugate (VDC) for a cancer that affects the eye into late-sta
ISA Pharmaceuticals is planning to take its COVID-19 immunotherapy into the clinic, aiming to harness the power of T-cells to prevent the disease from becoming serious in infected patients.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.